Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Day Two At BIO CEO: Deal Value Up, Deal Volume Down

This article was originally published in The Pink Sheet Daily

Executive Summary

The Let’s Make a Deal panel looked forward to more big product-focused Genzyme/Alnylam type deals in 2014 in a deal landscape changed by a robust pubic market and by caution on the part of big pharma; BIO chair Rachel King on 2014 priorities; Stallergenes prepares to launch Oralair

Advertisement

Related Content

Riding High On Investor Enthusiasm, BIO CEO 2014 Opens In New York

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS076813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel